PHASEBIO PHARMACEUTICALS, INC.

Analyst Reco. PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

Apr. 19	First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc.	CI
Feb. 07	Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cowen Downgrades PhaseBio Pharmaceuticals to Market Perform From Outperform	22-10-25	MT
Stifel Nicolaus Downgrades PhaseBio Pharmaceuticals to Hold From Buy, Sets $1 Price Target	22-09-28	MT
Needham Downgrades PhaseBio Pharmaceuticals to Hold from Buy	22-09-28	MT
William Blair Downgrades PhaseBio Pharmaceuticals to Market Perform From Outperform	22-09-28	MT
Needham Adjusts Price Target on PhaseBio Pharmaceuticals to $8 From $10, Reiterates Buy Rating	22-08-15	MT
Needham Adjusts PhaseBio Pharmaceuticals' Price Target to $10 from $15, Keeps Buy Rating	22-03-28	MT
PHASEBIO PHARMACEUTICALS : Needham Adjusts Price Target on PhaseBio Pharmaceuticals to $19 From $18, Maintains Buy Rating	21-03-16	MT
PHASEBIO PHARMACEUTICALS : Stifel Adjusts PhaseBio Pharmaceuticals' Price Target to $8 from $11, Keeps Buy Rating	21-01-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer